Syncom Healthcare Ltd.
Snapshot View

4.06 ▼0%

28 June 2021, 04:00:00 P.M.

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.syncomhealthcare.com
Financial Indicators
Market Cap 16.48 Cr.
Earnings per share (EPS) -1.23 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 34.39 Trailing Twelve Months Ending 2021-03
Book Value / Share -4.33 Trailing Twelve Months Ending 2021-03
Price to Book Value -0.95 Calculated using Price: 4.12
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 4.00 Cr. 40,000,000 Shares
FaceValue 10
Company Profile

The Company was originally incorporated as Syncom Healthcare Limited on July 29, 2002 by Registrar of Companies, Maharashtra, Mumbai. The Certificate for Commencement of business was granted on August 2, 2002. The company has been promoted by Ajay Bankda & Jyoti Bankda. The company was formed for manufacturing, marketing & trading of pharmaceuticals formulations under its own brands in Ethical, OTC, Generic and Herbal market segment.

Initially it started its journey with the marketing of the pharmaceuticals products manufactured by others under its own brand and in year 2006, the company set up a State of Art manufacturing unit at Dehradun in Uttarakhand. The unit was commissioned in November, 2006. During the year ended March 31, 2007, the net profit before tax & extra-ordinary items, of the Company increased to Rs.331.38 lakh from Rs.32.20 lakh during the year ended March 31, 2006 due to commencement of manufacturing of the various products in its own manufacturing unit and marketing through a strong distribution network.

SHL started as a marketing Company, which was outsourcing its requirement of finished products (Under Its Own Brand And Drug License) from other formulation manufacturing units based in and around Indore. Presently also SHL is outsourcing some of its requirement of finished products. With these companies, Syncom has a purchase and sale arrangement where the supplier unit is manufacturing SHL’s products on SHL’s specification and under SHL’s quality control under which SHL controls the quality of raw material, their sourcing by the supplier as well as production in the units of these suppliers. The manufactured goods, manufactured for SHL are sold to SHL on pre-decided order prices for each formulation product so manufactured.

To cater the diversified and increased demand the Company planned to set up its own pharmaceutical manufacturing facilities. Accordingly, the company set up a manufacturing facility at Dehradun in the state of Uttrakhand, which is a Tax free & duty free Zone. The Company set up its Plant at Dehradun and it started the commercial production in November, 2006. Presently Company is Manufacturing, Marketing and Distributing its Pharmaceutical Formulations under own Brands of Ethical, OTC, Generic and Herbal market segment.

Product range of the company:

Syncom has presence in Pharmaceuticals Formulations which can be categorized in 4 broad categories i.e. Generic, OTC, Ethical and Herbal. The company manufactures a range of products such as Ethical drugs, Generic drugs, over the counter drugs (OTC) and Herbal formulations in various dosage forms and markets them under the trade mark ‘Syncom’ which is a registered trademark in the name of Syncom Healthcare Limited. The company also undertakes contract manufacturing for large variety of pharmaceutical formulations for a number of other pharmaceutical companies of national and international repute such as Lupin Limited, Nicholas Piramal India Ltd, Galpha Laboratories Limited, Percos India Pvt. Ltd etc. (under their own brands) located in India.

The company manufactures various dosage forms, which include tablets, capsules, eye/ear drops, ointment and creams and dry syrups. The company has an established product-marketing network covering both metro and minimetro cities, which enable it to reach the existing and potential customers through the network of distributors and dealers spread across the country. For the purpose of marketing the various products, the Company’s business has been categorized as Branded Generic Division, Over the Counter (OTC), Ethical division and Contract Manufacturing Division.

The Company is producing more than 130 products in Generic segment which includes CTZ, Profeed, Nimjet, Divoron, Gentijet, Ciprojet, etc.

Apart form Generic, the Company has developed presence in OTC Segment. The Company is producing more than 40 products in this segment which include Fastac, Q-coril, Triple action, Pandrop, Syncom Gripe Water, etc. Having built-up a presence in Generic & OTC segment and as a measure to expand and grow, the Company has also entered into Ethical segment. Syncom has developed more than 20 products in this segment which includes Fresca, Flusa, Nutone, Busera, etc.

Syncom is also having presence in Herbal segment with around 25 products which includes Patton, Attom, Narisudha, Salony Cream, etc.

Milestones:

  • 2002 - Incorporation of Syncom Healthcare Limited
  • 2002 - Syncom Healthcare Limited started marketing operations
  • 2005 - Commenced setting up of manufacturing facility at Selaqui, Dehradun
  • 2006 - Start of commercial production at Dehradun Industrial Unit for its own marketing
  • 2007 - Entered into agreement for Contract manufacturing with Lupin Limited, Galpha Laboratories, Nicholas Piramal, etc. Pharmaceutical Companies for manufacturing its various range of products.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
-1.46%
1 Month
-1.46%
3 Month
+18.71%
6 Month
+42.46%
1 Year
+137.43%
2 Year
+286.67%
5 Year
-52.24%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 0.10 0.13 -2.71 -2.33 -2.20 -66.16 -151.43 -238.67
Return on Capital Employed (%) 1.79 1.90 -1.78 -0.40 -0.54 -45.67 -94.84 -37.68 -66.73
Return on Assets (%) 0.09 0.10 -1.92 -1.81 -1.82 -50.03 -73.53 -20.70 -34.83

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 183 172 168 164 160 76 10 -1 -12
Non Curr. Liab. 6 10 7 7 4 9 5 12 12
Curr. Liab. 43 68 53 25 29 33 45 38 18
Minority Int.
Equity & Liab. 232 251 227 195 194 117 61 49 18
Non Curr. Assets 135 138 141 129 125 67 19 15 13
Curr. Assets 98 112 84 64 68 51 42 34 5
Misc. Exp. not W/O 2 1 1
Total Assets 232 251 227 195 194 117 61 49 18

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 86 94 64 62 63 53 42 64 20
Other Income 4 2 3 3 3 2 0 0 0
Total Income 90 97 67 65 66 55 42 64 20
Total Expenditure -84 -90 -67 -60 -62 -55 -47 -66 -22
PBIDT 6 6 0 5 4 0 -5 -2 -2
Interest -2 -4 -4 -5 -3 -3 0 0 0
Depreciation -2 -2 -4 -5 -5 -5 -4 -3 -2
Taxation -1 0 3 2 1 -8
Exceptional Items -62 -57 -7 -8
PAT 0 0 -5 -4 -4 -78 -66 -11 -12

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -101 104 5 11 0 4 6 1 0
Cash Fr. Inv. 9 -108 -6 2 1 5 -1 0 1
Cash Fr. Finan. 2 5 1 -13 -1 -10 -5 -1 0
Net Change -89 1 -1 0 0 -1 0 0 0
Cash & Cash Eqvt 0 1 1 0 1 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2018-12 (%) 2019-03 (%) 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%)
Promoter 25.00 25.00 25.00 25.00 25.00 25.00 0.13 0.13 0.13
Public 75.00 75.00 75.00 75.00 75.00 75.00 99.87 99.87 99.87
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 09 Jul 2021
Compliance Certificate For The Period Ended 31St March 2021
Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that activities in relation in both physical and electronic share transfer facility are maintained during the period 01 October 2020 to 31st March 2021 by the Companys Registrar and Share Transfer Agent viz. Link Intime India Private Limited which is a SEBI approved Category-I Registrar and Transfer Agent registered with Securities and Exchange Board of India having Registration Number: INR000004058
Thu, 08 Jul 2021
Statement Of Investor Complaints For The Quarter Ended 31St March 2021 Pursuant To Regulation 13(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Statement of Investor Complaints for the quarter ended 31st March 2021 pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
Thu, 08 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended March 31 2021

Technical Scans View Details

No Scans Found

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 703.00 +2.2%
Divi's Laboratories Ltd. 128,656.69 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,672.65 -1.2%
Cipla Ltd. 71,170.06 883.10 -0.8%
Cadila Healthcare Ltd. 58,547.84 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,028.55 0.0%
Aurobindo Pharma Ltd. 53,214.94 908.25 -0.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 29.59 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 908.25 -0.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 3.88 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 908.25 -0.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 0.18 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 908.25 -0.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 10.09 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 908.25 -0.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 12.53 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 908.25 -0.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 908.25 -0.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 908.25 -0.8%